Navigation Links
Study Published in Molecular Therapy Shows that Immune Response to FANG™ Personalized Cancer Therapeutic Correlates with Prolonged Survival in Patients with Advanced Stage Cancer
Date:3/1/2012

DALLAS, March 1, 2012 /PRNewswire/ -- Today Gradalis, Inc., announced that FANG™, the company's tumor-based personalized cancer therapeutic, elicits a robust and lasting immune response, resulting in statistically-significant prolonged survival in patients with advanced stage disease. The Phase 1 study, published today in the Nature Publishing Group journal Molecular Therapy, showed that treatment with FANG significantly increased survival in patients with advanced stage cancer compared to patients who received other forms of treatment in this non-randomized study.

The study evaluated 46 patients with varying tumor types, including melanoma, colorectal, breast, ovarian and hepatocellular cancers. A personalized FANG vaccine was manufactured from tumors removed from 42 of the 46 patients, and 27 patients received one monthly dose of the vaccine for up to 12 months. Twenty-three of the 27 patients receiving FANG achieved stable disease within two months of dose initiation. Median survival for the FANG group was 554 days compared to 132 days for the group that did not receive FANG. (P<0.0001) The "no FANG" group included 18 patients who had vaccine made but did not receive injections due to progression of disease or pursuit of other treatment options. FANG was well tolerated by all patients, and there were no treatment-related serious adverse events.

"The pronounced survival benefit achieved by FANG in patients with multiple tumor types is quite remarkable, and randomized Phase 2 trials are currently underway verifying these results," said John Nemunaitis, M.D., executive medical director of the Mary Crowley Cancer Research Centers and chief medical officer and co-founder of Gradalis. "The benefit is likely attributed to the triad approach which is designed into the vaccine to maximize its effect.  FANG is not only manufactured using each individuals' tumor to assure exposure to the appropriate antigens, but it also activates
'/>"/>

SOURCE Gradalis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BrainCells Inc. Announces the Successful Completion of the Single Ascending Dose Study With BCI-838 and the Initiation of the Multiple Ascending Dose Study
2. Current Study Offers Window into Automation & Outsourcing Practices Within Top Pharmaceutical Market Research Groups
3. Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain
4. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
5. Preclinical Study Examines Use of nContacts Technology in Enabling a Percutaneous Device Approach to Epicardial Ablation
6. CHPA Responds to Prescription Mandate Cost Implications Outlined in Oklahoma Economic Impact Study
7. Medical Device Study Examines Use of Emerging Markets and Outsourcing for Clinical Activities
8. Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
9. Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
10. Understand the Lessons Learned from the FDA QbD Pilot Programme - Case Study Merck Serono
11. SCOLR Pharmas Partner to Commence Bioequivalence Study of Ondansetron
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... , Aug. 30, 2014  Boston Scientific ... NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical ... trial investigating vagus nerve stimulation (VNS) for the ... Ph.D., Professor of Therapeutics and Cardiology and Director ... National de la Sante et de la Recherche ...
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research Report ... 2009-2019 is a professional and in-depth market survey ... industry . The report firstly reviews the basic ... application and manufacturing technology. The report then explores ... Scanner listing their product specification, capacity, Production value, ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
... Osteotech, Inc. (Nasdaq: OSTE ), a leader in the ... the Company,s first quarter ended March 31, 2010 financial ... May 10, 2010 .  The management team of Osteotech will host ... , at 9:00 a.m. (EDT) to discuss the Company,s ...
... Doctora Aliza, editor in chief of VidaySalud.com and expert health commentator for the ... Latino Legislative Caucus during a special Assembly floor session at the California Capitol ... , (Photo: ... "Doctor Aliza ...
Cached Medicine Technology:Osteotech Announces First Quarter 2010 Financial Results Release and Conference Call 2Latino Spirit Award For VidaySalud.com's Doctora Aliza 2
(Date:8/31/2014)... Obese youths have a nearly six fold risk ... ,22 000 young people from the PEP Family ... Professor Peter Schwandt from Germany. , Professor Schwandt ... children and adolescents is continuing to rise in ... considered a driving force for cardiovascular disease, we ...
(Date:8/31/2014)... California (PRWEB) August 31, 2014 ... environmentally harmful disc brake dust at the source ... , Problem: Millions of vehicles globally emit brake ... ingredients in the friction materials (disc brake pads) ... the nations’ water systems. For example, copper impairs ...
(Date:8/31/2014)... 2014 Priya Khan, Director of ... concern over misinformation about weight-loss supplements saying, “Consumers ... often, misleading information being propagated by unscrupulous companies ... are weighing in on the subject. , NutriGold’s ... and especially weight-loss products and to provide them ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 To make ... supplement brand they can trust, NutriGold is shipping complimentary ... A form has been set up to make taking ... , According to Priya Khan, Director of Research ... customers purchase one of our products, they are entrusting ...
(Date:8/31/2014)... 2014 “Prohibition is our history,” ... our future: the present ~ that’s political.” , ... , new on the Bryan William Brickner Blog, ... system (CS) modulation and homeostasis - including one ... use. The Publius CS update includes: heteromerization ...
Breaking Medicine News(10 mins):Health News:Obese youths have a nearly 6 fold risk of hypertension 2Health News:CBPModular Technology with Global Patent Coverage Solves Vehicle Wheel Brake Dust Problem 2Health News:New Reasons to Verify Label Claims on Weight-loss Products Before Buying 2Health News:New Reasons to Verify Label Claims on Weight-loss Products Before Buying 3Health News:Whole-food Supplement Samples Now Offered by NutriGold 2Health News:Whole-food Supplement Samples Now Offered by NutriGold 3Health News:Homeostasis: Publius’ Alcohol Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2
... of Michigan evolutionary biologist Jianzhi "George" Zhang, has uncovered ... a sex determiner in honey bees. These novel inputs ... methods to breed honeybees, who are effective pollinators of ... findings of Zhang and collaborators are published in a ...
... to pain.In the study conducted on rats, the development// ... expression of that particular gene after a nerve injury ... of new painkillers. ,"Studies in volunteers showed ... variant that protects them from pain somewhat, and three ...
... disease is to be resumed and researchers from Southampton University ... ,The progress of the disease was supposed to be reversed ... the disease. But during the second phase of the trial, ... the study was brought to a halt for safety ...
... plastic and reconstructive surgeon has been given the go-ahead ... the Royal Free Hospital, London to select four patients ... College of Surgeons has called for caution with leading ... surgery promises to transform the lives of hundreds of ...
... implanted in 65,000 dogs in Shanghai to improve canine management ... at curbing// rabies in provinces of Yunnan and Shandong drew ... ID number. To access information about the dog - photo, ... have to access the ID number. ,Chip developer ...
... Gleneagles Hospitals has asked the West Bengal government for 10 ... here for setting up// a Rs.1.5 billion institute. ... research in the medical field, said V. Satyanarayana Reddy, CEO, ... the government to identify and hand over a site for ...
Cached Medicine News:Health News:Breeding success by delving into the honey bee sex gene 2Health News:Breeding success by delving into the honey bee sex gene 3Health News:Gene determines pain threshold... 2Health News:Alzheimer's Vaccine- A Realistic Prospect 2Health News:Green Signal given to Full-Face Transplants 2Health News:Green Signal given to Full-Face Transplants 3
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 6.0mm....
Subretinal Aspiration Cannula, Curved; 20g (0.90) x 1" (25mm); Tip Extension: 6.5mm, 27g (0.40); Angled at 60°, 2.5mm from Tip....
Subretinal Fluid Cannula, Straight; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip....
Medicine Products: